Anticoagulants, Antiplatelets, and Thrombolytics
Shaker A. Mousa
Humana Press, Aug 17, 2010 - Medical - 316 pages
During the past decade, remarkable progress has been made in the development of newer drugs to prevent and treat thromboembolic disorders, such as oral direct anti-Xa and anti-IIa antagonists, as well as oral antiplatelet ADP antagonists with rapid onset and offset. In addition, there has been concentrated effort aimed at identifying novel uses of traditional antithrombotic drugs, such as aspirin, heparin, and oral anticoagulants, as well as combinations of agents, such as more than one antiplatelet, antiplatelet with anticoagulant, antiplatelet with or without thrombolytic. Anticoagulants, Antiplatelets, and Thrombolytics, Second Edition provides updates on various strategies in thrombosis, experimental models, and clinical and recent advances in the discovery and development of novel antithrombotics. As a volume in the highly successful Methods in Molecular BiologyTM series, this collection provides the kind of detailed description and implementation advice that is crucial for getting optimal results. Easy to use and up to date, Anticoagulants, Antiplatelets, and Thrombolytics, Second Edition is an ideal guide for researchers aiming for the future of this vital field, focusing on the prevention of thromboembolic disorders and the protection of the vascular endothelium.
What people are saying - Write a review
We haven't found any reviews in the usual places.
In Vivo Models for the Evaluation of Antithrombotics and Thrombolytics
Heparin and LowMolecular Weight Heparins in Thrombosis and Beyond
Laboratory Methods and Management of Patients with HeparinInduced
8 other sections not shown
Other editions - View all
acute adhesion agents angiogenesis animal models anticoagulant antiplatelet therapy antithrombotic Argatroban arterial thrombosis aspirin assay binding blood flow cancer CFRs Circulation clinical clopidogrel clot coagulation collagen coronary artery dabigatran Direct Factor Xa dose drug effects efficacy endothelial enoxaparin evaluation experimental factor Xa factor Xa inhibitor fibrin fibrinogen fondaparinux gene genetic glycoprotein GPIIb/IIIa GPIIb/IIIa antagonists heparin-induced thrombocytopenia hirudin HIT antibodies human IIb/IIIa induced inhibition injection integrin interactions intravenous lepirudin LMWH major bleeding metastasis mice molecular molecules monitoring Mousa myocardial infarction occlusion P-selectin pain patients pharmacokinetics Pharmacol plasma plasminogen platelet activation platelet aggregation potential prasugrel prevention protein rabbit randomized rats receptor reduced risk rivaroxaban role sickle cell disease stenosis stroke surgery syndrome TFPI therapeutic Thromb Haemost Thromb Res thrombin inhibitors thrombolytic thrombotic thrombus formation tinzaparin tion tissue factor treatment trial tumor cells vascular versus vessel vitro vivo warfarin weight heparin ximelagatran